Search Results

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) (IM048022) MOA: Cereblon E3 ubiquitin ligase modulating agent, IMiD (thalidomide and its analogues) Key Eligibility Criteria: Confirmed diagnosis of symptomatic multiple myeloma (MM) Eastern…

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Patients with Advanced, EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer who have Progressed after Treatment with Osimertinib (ONC-003) MOA: Quaratusugene ozeplasmid (REQORSA™, GPX-001) has been shown to modulate the immune system Key Eligibility Criteria: Histologically/cytologically documented NSCLC Stage III/IV…

A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Trastuzumab-based Therapy (FLAMINGO-01) MOA: GLSI-100 is the individual administration of GP2, a nine amino acid peptide of the HER2/neu protein,…

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry) Brief Summary:  The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary…

Jaynah Mistry is a physician assistant with over 8 years of experience in inpatient hospital medicine. She graduated with her masters from Rochester Institute of Technology in 2016. She has been with MOH since January of 2022.